PMEF
VTGN icon

Point72 Middle East FZE’s VistaGen Therapeutics VTGN Stock Holding History

Point72 Middle East FZE’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,720
Closed -$14.4K – 1917
2023
Q2 		$14.4K Buy
+7,720
New +$27.1K ﹤0.01% 1396

Other funds holding VTGN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's VTGN Position: Q3 2023 in Review

Point72 Middle East FZE sold out of VistaGen Therapeutics (VTGN) in Q3 2023, closing a stake of 7,720 shares — an estimated $14.4K sold.

Point72 Middle East FZE first reported a position in VTGN in Q2 2023 and held it in 1 quarter. The position peaked at $14.4K in Q2 2023. 34 funds tracked by Wall St. Rank hold VTGN as of Q3 2023.

  • Point72 Middle East FZE reported no remaining VistaGen Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 7,720 VistaGen Therapeutics shares in Q3 2023, an estimated $14.4K.
  • Point72 Middle East FZE first reported a position in VistaGen Therapeutics in Q2 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's VistaGen Therapeutics position peaked at $14.4K in Q2 2023.
  • 34 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.